

Shilpa S Tummala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8794568/publications.pdf>

Version: 2024-02-01

14
papers

411
citations

933447

10
h-index

1372567

10
g-index

14
all docs

14
docs citations

14
times ranked

982
citing authors

#	ARTICLE	IF	CITATIONS
1	Sirtuin activation targets IDH-mutant tumors. <i>Neuro-Oncology</i> , 2021, 23, 53-62.	1.2	15
2	A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma. <i>Cancer Research</i> , 2020, 80, 5330-5343.	0.9	19
3	Accelerated progression of IDH mutant glioma after first recurrence. <i>Neuro-Oncology</i> , 2019, 21, 669-677.	1.2	38
4	PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4375-4387.	7.0	26
5	Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. <i>Journal of Neuro-Oncology</i> , 2019, 141, 327-335.	2.9	72
6	A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas. <i>Neurosurgery</i> , 2019, 85, 204-210.	1.1	28
7	MNGI-37. DMD GENOMIC DELETIONS CHARACTERIZE A SUBSET OF PROGRESSIVE/HIGHER-GRADE MENINGIOMAS WITH POOR OUTCOME. <i>Neuro-Oncology</i> , 2018, 20, vi157-vi157.	1.2	0
8	TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations. <i>Acta Neuropathologica Communications</i> , 2018, 6, 106.	5.2	18
9	Genotype-targeted local therapy of glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8388-E8394.	7.1	40
10	DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. <i>Acta Neuropathologica</i> , 2018, 136, 779-792.	7.7	66
11	151 TERT Promoter Mutations in Progressive Treatment-resistant Meningiomas. <i>Neurosurgery</i> , 2017, 64, 236-237.	1.1	0
12	NIMG-62. RADIOLOGIC RESPONSE RATE OF IDH MUTANT GLIOMA FOLLOWING RADIATION TREATMENT: A RETROSPECTIVE ANALYSIS. <i>Neuro-Oncology</i> , 2017, 19, vi156-vi156.	1.2	0
13	Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. <i>Oncotarget</i> , 2017, 8, 109228-109237.	1.8	89
14	SURG-05 MOLECULAR CORRELATES OF TUMOR SIZE AND MRI CONTRAST ENHANCEMENT IN A COHORT OF LOWER-GRADE GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2015, 17, v215.1-v215.	1.2	0